A primary mechanism targeted by cholinesterase inhibitors used to treat Alzheimer’s disease is which?

A primary mechanism targeted by cholinesterase inhibitors used to treat Alzheimer’s disease is which?

• A. Inhibition of acetylcholinesterase
• B. Activation of NMDA receptors
• C. Inhibition of GABA receptors
• D. Antagonism of dopamine receptors

Answer: (A)

Cholinesterase inhibitors work by preventing the breakdown of acetylcholine, which boosts cholinergic signaling in brain regions essential for memory and cognition. In Alzheimer's disease, there is a loss of cholinergic neurons, so keeping acetylcholine around longer helps improve or stabilize cognitive symptoms for some time. By inhibiting acetylcholinesterase, these drugs raise acetylcholine levels at synapses. The other mechanisms listed don’t fit this drug class. Activating NMDA receptors isn’t how cholinesterase inhibitors work (memantine, an NMDA receptor antagonist, is used in later stages). Inhibiting GABA receptors would increase neuronal excitation in a way not targeted by these agents, and antagonizing dopamine receptors relates to antipsychotic medications rather than cholinergic therapy.

Cholinesterase inhibitors work by preventing the breakdown of acetylcholine, which boosts cholinergic signaling in brain regions essential for memory and cognition. In Alzheimer's disease, there is a loss of cholinergic neurons, so keeping acetylcholine around longer helps improve or stabilize cognitive symptoms for some time. By inhibiting acetylcholinesterase, these drugs raise acetylcholine levels at synapses.

The other mechanisms listed don’t fit this drug class. Activating NMDA receptors isn’t how cholinesterase inhibitors work (memantine, an NMDA receptor antagonist, is used in later stages). Inhibiting GABA receptors would increase neuronal excitation in a way not targeted by these agents, and antagonizing dopamine receptors relates to antipsychotic medications rather than cholinergic therapy.